Original Article

Metabolomics

, Volume 11, Issue 2, pp 477-486

Open Access This content is freely available online to anyone, anywhere at any time.

Metabolic profiling of a transgenic Caenorhabditis elegans Alzheimer model

  • Roel Van AsscheAffiliated withFunctional Genomics and Proteomics, Department of Biology, KU Leuven Email author 
  • , Liesbet TemmermanAffiliated withFunctional Genomics and Proteomics, Department of Biology, KU Leuven
  • , Daniel A. DiasAffiliated withMetabolomics Australia, School of Botany, University of Melbourne
  • , Berin BoughtonAffiliated withMetabolomics Australia, School of Botany, University of Melbourne
  • , Kurt BoonenAffiliated withFunctional Genomics and Proteomics, Department of Biology, KU Leuven
  • , Bart P. BraeckmanAffiliated withLaboratory for Aging Physiology and Molecular Evolution, Department of Biology, Ghent University
  • , Liliane SchoofsAffiliated withFunctional Genomics and Proteomics, Department of Biology, KU Leuven
  • , Ute RoessnerAffiliated withMetabolomics Australia, School of Botany, University of Melbourne

Abstract

Despite decades of research, no early-onset biomarkers are currently available for Alzheimer’s disease, a cureless neurodegenerative disease afflicting millions worldwide. In this study, transgenic Caenorhabditis elegans were used to investigate changes in the metabolome after induced expression of amyloid-β. GC- and LC–MS-based platforms determined a total of 157 differential features. Some of these were identified using in-house (GC–MS) or public libraries (LC–MS), revealing changes in allantoin, cystathionine and tyrosine levels. Since C. elegans is far better suited to metabolomics studies than most other model systems, the accordance of these findings with vertebrate literature is promising and argues for further use of C. elegans as a model of human pathology in the study of AD.

Keywords

Metabolomics Metabolic profiling Caenorhabditis elegans Alzheimer’s disease Amyloid-β